<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LINEZOLID </span><br/>(lin-e-zo'lid)<br/><span class="topboxtradename">Zyvox, </span><span class="topboxtradename">Zyvoxam <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic, oxazolidinone</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>400 mg, 600 mg tablets; 100 mg/5 mL suspension; 200 mg, 400 mg, 600 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic antibiotic of a new class, the oxazolidinone group, that is bacteriocidal against gram-positive, gram-negative,
         and anaerobic bacteria. It binds to a site on the bacterial 23S ribosomal RNA of the bacteria which prevents the bacterial
         RNA translation process.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Bacteriostatic against <i>enterococci</i> and <i>staphylococci,</i> and bacteriocidal against <i>streptococci</i>. These include <i>Enterococcus faecium</i> [vancomycin-resistant strains (VREF) only, <i>Staphylococcus aureus</i> including methicillin-resistant (MRSA)] strains.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of vancomycin-resistant (VREF) <i>Enterococcus faecium,</i> nosocomial pneumonia, complicated and uncomplicated skin and skin structure infections, community-acquired pneumonia due
         to susceptible gram-positive organisms.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to linezolid, pregnancy (category C), lactation, neonates. Safety and effectiveness in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation, history of thrombocytopenia, thrombocytopenia; patients on <small>MAOI</small>, or serotonin reuptake inhibitors, or adrenergic agents, active alcoholism, anemia, bleeding, bone marrow suppression, cardiac
         arrhythmias, cardiac disease, cerebrovascular disease, chemotherapy, coagulopathy, colitis, diarrhea, hypertension, hyperthyroidism,
         leukopenia, MI, PKU disorder, radiographic contrast administration, spinal anesthesia, surgery, hypertension; phenylketonuria;
         carcinoid syndrome.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Vancomycin-Resistant <i>Enterococcus faecium</i>
</span><br/><span class="rdage">Adult/Adolescent:</span> <span class="rdroute">PO/IV</span>
<i>&gt;12 y,</i> 600 mg q12h <small>x</small> 1428 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span>
<i>211 y, 10</i> mg/kg q8 h <small>x</small> 1428 d<br/><br/><span class="indicationtitle">Nosocomial or Community-Acquired Pneumonia, Complicated Skin Infections</span><br/><span class="rdage">Adult/Adolescent:</span> <span class="rdroute">PO/IV</span>
<i>&gt;12 y,</i> 600 mg q12h <small>x</small> 1014 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span>
<i>511</i>
<i>y,</i> 10 mg/kg q8h <small>x</small> 1014 d<br/><br/><span class="indicationtitle">Uncomplicated Skin Infections</span><br/><span class="rdage">Adult/Adolescent:</span> <span class="rdroute">PO</span>
<i>&gt;12 y,</i> 600 mg q12h <small>x</small> 1014 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i> 10 mg/kg q8h <small>x</small> 1014 d <i>511 y,</i> 10 mg/kg q12h <small>x</small> 1014 d<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: No dosage adjustment is necessary when switching from IV to oral administration.
         		
      </p><span class="adminroutetype">Oral</span><br/><ul>
<li>Reconstitute suspension by adding 123 mL distilled water in two portions; after adding first half, shake to wet all of the
            powder, then add second half of water and shake vigorously to produce a uniform suspension with a concentration of 100 mg/5
            mL.
         </li>
<li>Before each use, mix suspension by inverting bottle 35 times, but <small>DO NOT SHAKE</small>. Discard unused suspension after 21 d.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> IV solution is supplied in a single-use, ready-to-use infusion bag. Remove from protective wrap immediately prior to use.
                  Check for minute leaks by firmly squeezing bag. Discard if leaks are detected.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Do not use infusion bag in a series connection. Give over 30120 min. If IV line is used to infuse other drugs, flush
                  before and after with D5W, NS, or LR.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Ceftriaxone,</b>
<b>erythromycin,</b>
<b>trimethoprim-sulfamethoxazole.</b>
<span class="incompattype">Y-site:</span>
<b>Amphotericin B,</b>
<b>ceftriaxone,</b>
<b>chlorpromazine,</b>
<b>diazepam,</b>
<b>pentamidine,</b>
<b>erythromycin,</b>
<b>phenytoin,</b>
<b>trimethoprim-sulfamethoxazole.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 25° C (77° F) preferred; 15°30° C (59°86° F) permitted. Protect from light
            and keep bottles tightly closed.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever. <span class="typehead">GI:</span> Diarrhea, nausea, vomiting, constipation, taste alteration, abnormal LFTs, tongue discoloration. <span class="typehead">Hematologic:</span> Thrombocytopenia, leukopenia. <span class="typehead">CNS:</span> Headache, insomnia, dizziness. <span class="typehead">Skin:</span> Rash. <span class="typehead">Urogenital:</span> Vaginal moniliasis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">mao inhibitors</span> may cause hypertensive crisis; <b>pseudoephedrine</b> may cause elevated BP; may cause <b>serotonin</b> syndrome with <b>citalopram,</b>
<b>escitalopram.</b>
<span class="typehead">Food:</span>
<span class="classification">tyramine containing food</span> may cause elevated BP. <span class="typehead">Herbal:</span>
<b>Ginseng,</b>
<b>ephedra,</b>
<b>ma huang</b> may lead to elevated BP, headache, nervousness. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly or extensively absorbed, 100% bioavailable. <span class="typehead">Peak:</span> 12 h PO. <span class="typehead">Distribution:</span> 31% protein bound. <span class="typehead">Metabolism:</span> Metabolized by oxidation. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 67 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of: Bleeding; hypertension; or pseudomembranous colitis that begins with diarrhea.</li>
<li>Lab tests: C&amp;S before initiating therapy and during therapy as indicated; drug may be started pending results. Monitor complete
            blood count, including platelet count and Hgb &amp; Hct, in those at risk for bleeding or with &gt;2 wk of linezolid therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to physician promptly: Onset of diarrhea; easy bruising or bleeding of any type; or S&amp;S of superinfection
            (see Appendix F).
         </li>
<li>Avoid foods and beverages high in tyramine (e.g., aged, fermented, pickled, or smoked foods, and beverages). Limit tyramine
            intake to &gt;100 mg per meal (see <i>Information for Patients</i> provided by the manufacturer).
         </li>
<li>Do not take OTC cold remedies or decongestants without consulting physician.</li>
<li>Note for phenylketonurics: Each 5 mL oral suspension contains 20 mg phenylalanine.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>